Hospital
Lake Regional Health System
Lake Regional Health System was paid $23.69M by Medicaid between Jan 2018 and Dec 2024, across 145 billing codes. Its largest line is X4011, State-specific procedure code — 17% of everything it billed.
33Billing provider infoLAKE REGIONAL HEALTH SYSTEM
OSAGE BEACH, MO 65065
OSAGE BEACH, MO 65065
33aNPI1386619450assigned 02/21/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$23.69M
24GClaims276,947
24DCodes billed145
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Missouri
Rank by total paid#15 of 74
Median peer was paid$4.44M
This provider vs. median5.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MCROBERTS, KEVIN controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 33,547 | $8.85M | |
| 2019 | 32,671 | $5.37M | |
| 2020 | 32,391 | $2.69M | |
| 2021 | 39,007 | $1.07M | |
| 2022 | 56,399 | $2.31M | |
| 2023 | 55,693 | $2.22M | |
| 2024incomplete | 27,239 | $1.19M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| X4011 | State-specific procedure code | 17% | 13,959 | 13,215 | $4.14M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 11% | 42,347 | 36,409 | $2.56M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.9% | 10,828 | 9,997 | $2.10M |
| 80053 | Comprehensive metabolic panel | 8.7% | 36,321 | 31,755 | $2.05M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.5% | 16,684 | 15,765 | $2.01M |
| Y7506 | 6.5% | 11,533 | 9,406 | $1.53M | |
| 81001 | 6.0% | 11,506 | 10,901 | $1.41M | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.4% | 8,396 | 7,719 | $560K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.3% | 2,092 | 1,901 | $549K |
| X4006 | 2.2% | 850 | 417 | $526K | |
| 71045 | Radiologic examination, chest; single view | 2.2% | 7,031 | 6,518 | $522K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.0% | 4,646 | 4,317 | $483K |
133 more codes
| 36415 | Collection of venous blood by venipuncture | 1.2% | 6,549 | $289K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.2% | 11,928 | $287K |
| 83690 | 1.2% | 4,214 | $276K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,377 | $223K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,005 | $201K |
| X4003 | <1% | 2,037 | $198K | |
| 82150 | <1% | 2,673 | $186K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,147 | $177K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 611 | $172K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,039 | $162K |
| 87400 | <1% | 1,376 | $155K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,983 | $143K |
| 84484 | <1% | 4,019 | $135K | |
| 82550 | <1% | 3,396 | $127K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 718 | $114K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,300 | $112K |
| Y7507 | <1% | 410 | $110K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 7,517 | $110K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,553 | $110K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 801 | $108K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,212 | $103K |
| 93017 | <1% | 757 | $102K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,384 | $97K |
| 87081 | <1% | 401 | $93K | |
| 85610 | <1% | 2,247 | $83K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 506 | $78K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 542 | $67K |
| 88312 | <1% | 908 | $64K | |
| 87581 | <1% | 76 | $60K | |
| 87486 | <1% | 76 | $60K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 75 | $59K |
| 59025 | Fetal non-stress test | <1% | 616 | $57K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 59 | $54K |
| 94726 | <1% | 416 | $51K | |
| 83735 | <1% | 3,386 | $50K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,672 | $49K |
| 94060 | <1% | 436 | $49K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,371 | $40K |
| 86141 | <1% | 768 | $39K | |
| 36591 | <1% | 1,989 | $39K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 625 | $36K |
| 85730 | <1% | 1,495 | $35K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 547 | $34K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 534 | $27K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 376 | $23K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,036 | $20K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,292 | $18K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 511 | $17K |
| 94729 | <1% | 260 | $17K | |
| 95811 | <1% | 38 | $16K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 118 | $15K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 31 | $14K |
| G0378 | Hospital observation service, per hour | <1% | 26 | $14K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 769 | $14K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 740 | $13K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 16 | $11K |
| 86592 | <1% | 451 | $11K | |
| 86900 | <1% | 86 | $11K | |
| 83605 | <1% | 167 | $10K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 12 | $10K |
| 86850 | <1% | 100 | $10K | |
| 86901 | <1% | 100 | $10K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 28 | $10K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 431 | $9K |
| J3490 | Unclassified drugs | <1% | 1,168 | $9K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 199 | $9K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 266 | $9K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 35 | $8K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 87 | $7K |
| 80061 | Lipid panel | <1% | 1,205 | $7K |
| 81025 | <1% | 243 | $6K | |
| 85018 | <1% | 917 | $6K | |
| 87070 | <1% | 1,234 | $6K | |
| 43235 | <1% | 23 | $5K | |
| 84703 | <1% | 589 | $5K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 42 | $5K |
| A4641 | Radiopharmaceutical, diagnostic, not otherwise classified | <1% | 335 | $5K |
| 83880 | <1% | 193 | $5K | |
| 87807 | <1% | 528 | $4K | |
| 87653 | <1% | 143 | $4K | |
| 81003 | <1% | 3,024 | $4K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 45 | $3K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 58 | $3K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 43 | $3K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 104 | $3K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 689 | $3K |
| 82950 | <1% | 179 | $2K | |
| 87634 | <1% | 97 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 68 | $2K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 325 | $2K |
| 87905 | <1% | 12 | $2K | |
| 83655 | <1% | 235 | $1K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 30 | $1K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 57 | $1K |
| 86803 | <1% | 127 | $1K | |
| 84439 | <1% | 245 | $993.81 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 32 | $969.80 |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 66 | $900.04 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 169 | $846.16 |
| 76801 | <1% | 12 | $792.12 | |
| 74019 | <1% | 28 | $790.16 | |
| 85007 | <1% | 12 | $785.88 | |
| 85014 | <1% | 12 | $785.88 | |
| 85048 | <1% | 12 | $785.88 | |
| 85049 | <1% | 12 | $785.88 | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 13 | $690.69 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 70 | $677.95 |
| 80305 | <1% | 103 | $642.53 | |
| 85651 | <1% | 335 | $562.09 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 56 | $506.79 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 56 | $506.79 |
| 71250 | <1% | 15 | $482.74 | |
| 86787 | <1% | 131 | $474.23 | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 12 | $450.34 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 132 | $392.54 |
| 36416 | <1% | 40 | $333.66 | |
| 88300 | <1% | 13 | $189.50 | |
| 87040 | <1% | 30 | $163.04 | |
| 86140 | <1% | 50 | $117.95 | |
| 83615 | <1% | 31 | $103.36 | |
| 82607 | <1% | 15 | $86.62 | |
| 82746 | <1% | 15 | $84.44 | |
| 82728 | <1% | 14 | $66.04 | |
| 84466 | <1% | 14 | $61.79 | |
| 83540 | <1% | 14 | $31.31 | |
| 82553 | <1% | 13 | $20.80 | |
| 82962 | <1% | 14 | $17.70 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 14 | $10.80 |
| A9270 | Non-covered item or service | 0% | 168 | $0.00 |
| 99156 | 0% | 108 | $0.00 | |
| 87340 | 0% | 13 | $0.00 | |
| 86762 | 0% | 12 | $0.00 | |
| 74018 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCROBERTS, KEVIN (CEO)
| Provider | Location | Paid |
|---|---|---|
| Lake Regional Medical Management, INC. | Osage Beach, MO | $2.13M |
| Lake Regional Health System | Eldon, MO | $1.85M |
| Lake Regional Health System | Osage Beach, MO | $1.49M |
| Lake Regional Health System | Camdenton, MO | $1.36M |
| Lake Regional Health System | Osage Beach, MO | $1.03M |
| Lake Regional Health System | Lake Ozark, MO | $798K |
| Lake Regional Health System | Laurie, MO | $244K |
| Lake Regional Health System | Lebanon, MO | $209K |
| Lake Regional Health System | Iberia, MO | $113K |
| Lake Regional Health System | Osage Beach, MO | $77K |
| Lake Regional Health System | Camdenton, MO | $62K |
| Lake Regional Health System | Osage Beach, MO | $29K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.